Results from the FLAURA2 trial have come out this year and the results provide "compelling evidence that the addition of chemotherapy to osimertinib can provide a new option for patients and clinicians that further improves outcomes compared to osimertinib alone and, as such, can further delay treatment resistance and disease progression." There are several articles about this on the internet; here is one of them:
https://www.cancernetwork.com/view/osimertinib-chemo-improves-survival-vs-osimertinib-in-egfr-nsclc
The combination has been granted priority review by the FDA:
https://www.astrazeneca-us.com/media/press-releases/2023/tagrisso-plus-chemotherapy-granted-priority-review-in-the-us-for-patients-with-egfr-mutated-advanced-lung-cancer-10162023.html